Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 10/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 5/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17176468 | 0.87 | HTR3A (0.58) | HTR3ACFD | |
| SCHEMBL20646911 | 0.81 | HTR3A (0.39) | HTR3ACNR1CNR2CFDATM | |
| SCHEMBL17170594 | 0.80 | HTR3A (0.57) | HTR3ACNR1CNR2CFD | |
| SCHEMBL24247735 | 0.77 | CFD (0.50) | HTR3ACFD | |
| SCHEMBL17170619 | 0.77 | HTR3A (0.59) | HTR3ACNR1CNR2ATM | |
| SCHEMBL173832 | 0.73 | ATM (0.51) | ATM | |
| SCHEMBL20646928 | 0.73 | HTR3A (0.42) | HTR3ACNR1 | |
| SCHEMBL17163324 | 0.73 | HTR3A (1.00) | HTR3A | |
| SCHEMBL17163326 | 0.73 | HTR3A (1.00) | HTR3A | |
| SCHEMBL19068181 | 0.70 | HTR3A (0.57) | HTR3ACNR1CNR2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885CNR1 37/4885CNR2 47/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885CNR1 37/4885CNR2 47/4885 |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885CNR1 37/4885CNR2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.